79421-45-7

Basic information

• Product Name: 4-Hydroxy-1-(4-nitrophenyl)piperidine
• Synonyms: 4-Hydroxy-1-(4-nitrophenyl)piperidine;1-(4-Nitrophenyl)piperidin-4-ol, 4-(4-Hydroxypiperidin-1-yl)nitrobenzene;1-(4-Nitrophenyl)piperidin-4-ol
• CAS NO: 79421-45-7
• Molecular Formula: C₁₁H₁₄N₂O₃
• Molecular Weight: 222.25
• Mol File: 79421-45-7.mol

Chemical Properties

• Melting Point: 114-116 °C(Solv: isopropanol (67-63-0))
• Boiling Point: 421.5°C at 760 mmHg
• Flash Point: 208.7°C
• Appearance: /
• Density: 1.303g/cm³
• Vapor Pressure: 7.42E-08mmHg at 25°C
• Refractive Index: 1.611
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.69±0.20(Predicted)
• CAS DataBase Reference: 4-Hydroxy-1-(4-nitrophenyl)piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Hydroxy-1-(4-nitrophenyl)piperidine(79421-45-7)
• EPA Substance Registry System: 4-Hydroxy-1-(4-nitrophenyl)piperidine(79421-45-7)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 79421-45-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Hydroxy-1-(4-nitrophenyl)piperidine is used as an intermediate in the synthesis of various pharmaceuticals for its potential biological activities. Its derivatives have been studied for their potential as antipsychotic and anti-inflammatory agents, highlighting its importance in the development of new medications.
Used in Agrochemical Synthesis:
In the agrochemical industry, 4-Hydroxy-1-(4-nitrophenyl)piperidine is utilized as a precursor in the production of various agrochemicals, contributing to the development of effective pest control and crop protection solutions.
Used in Drug Research and Development:
4-Hydroxy-1-(4-nitrophenyl)piperidine is employed as a valuable compound in drug research and development due to its antimicrobial and antifungal properties. These characteristics make it a promising candidate for the creation of new antimicrobial agents to combat resistant strains and improve public health.
Used in Antimicrobial Applications:
4-Hydroxy-1-(4-nitrophenyl)piperidine is used as an antimicrobial agent for its ability to inhibit the growth of various microorganisms, making it a potential component in the development of new antibiotics and antifungal medications.
Used in Anti-inflammatory Applications:
4-Hydroxy-1-(4-nitrophenyl)piperidine is also used as an anti-inflammatory agent, given its potential to reduce inflammation and alleviate symptoms associated with inflammatory conditions, contributing to the advancement of treatments for various inflammatory diseases.

InChI:InChI=1/C11H14N2O3/c14-11-5-7-12(8-6-11)9-1-3-10(4-2-9)13(15)16/h1-4,11,14H,5-8H2

Upstream product

• 23499-01-6 1-(4-nitrophenyl)piperidin-4-one 
• 350-46-9 4-Fluoronitrobenzene 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 100-00-5 4-chlorobenzonitrile 
• 6574-15-8 1-(4-nitrophenyl)piperidine 

Downstream Products

• 1244967-96-1 N-(4-(4-hydroxypiperidin-1-yl)-phenyl)-4-((1-methylpyrrol-2-yl)-carbonyl)-1-piperazinecarboxamide 
• 211247-62-0 [1-(4-Amino-phenyl)-piperidin-4-yl]-dimethyl-amine 
• 211247-60-8 N,N-dimethyl-1-(4-nitrophenyl)piperidin-4-amine 
• 1415794-28-3 2-(1-(4-bromophenyl)piperidin-4-yloxy)ethanol 
• 1415794-27-2 tert-butyl 2-(1-(4-bromophenyl)piperidin-4-yloxy)acetate 
• 1415794-29-4 2-(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yloxy)ethanol 
• 142752-12-3 4-(4-hydroxypiperidin-1-yl)aniline 
• 23499-01-6 1-(4-nitrophenyl)piperidin-4-one 

Relevant articles and documents

Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor

Focal adhesion kinase (FAK) is a tyrosine kinase with prominent roles in protein scaffolding, migration, angiogenesis, and anchorage-independent cell survival and is an attractive target for the development of cancer therapeutics. However, current FAK inhibitors display dual kinase inhibition and/or significant activity on several kinases. Although multitargeted activity is at times therapeutically advantageous, such behavior can also lead to toxicity and confound chemical-biology studies. We report a novel series of small molecules based on a tricyclic pyrimidothiazolodiazepinone core that displays both high potency and selectivity for FAK. Structure-activity relationship (SAR) studies explored modifications to the thiazole, diazepinone, and aniline "tail,"which identified lead compound BJG-03-025. BJG-03-025 displays potent biochemical FAK inhibition (IC50 = 20 nM), excellent kinome selectivity, activity in 3D-culture breast and gastric cancer models, and favorable pharmacokinetic properties in mice. BJG-03-025 is a valuable chemical probe for evaluation of FAK-dependent biology.

Indazole formamide compound as well as preparation method and application thereof

The invention belongs to the field of chemical medicines, and particularly relates to an indazole formamide compound as well as a preparation method and application thereof. The invention provides anindazole carboxamide compound or a pharmaceutically acce

COMPOUNDS FOR TARGETED DEGRADATION OF BRD9

BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

Design, synthesis and biological evaluation of novel 7-amino-[1,2,4]triazolo[4,3-f]pteridinone, and 7-aminotetrazolo[1,5-f]pteridinone derivative as potent antitumor agents

To develop novel therapeutic agents with anticancer activities, two series of novel 7-amino-[1,2,4]triazolo[4,3-f]pteridinone, and 7-aminotetrazolo[1,5-f]pteridinone derivatives were designed and synthesized. All compounds were tested for anti-proliferative activities against five cancer cell lines. The structure-activity relationships (SARs) studies were conducted through the variation in two regions, the moiety of A ring and the terminal aniline B on pteridinone core. 1-Methyl-1,2,4-triazole derivative L7 with 2,6-dimethylpiperazine showed the most potent antiproliferative activity against A549, PC-3, HCT116, MCF-7 and MDA-MB-231 cell lines with IC50 values of 0.16 μM, 0.30 μM, 0.51 μM, 0.30 μM, and 0.70 μM, respectively. Combined with the results of the molecular docking and enzymatic studies, the PLK1 was very likely to be one of the drug targets of compound L7. Furthermore, to clarify the anticancer mechanism of compound L7, further explorations in the bioactivity were conducted. The results showed that compound L7 obviously inhibited proliferation of A549 cell lines, induced a great decrease in mitochondrial membrane potential leading to apoptosis of cancer cells, suppressed the migration of tumor cells, and arrested G1 phase of A549 cells.

2,4-dibasic miazines compound

The invention belongs to the field of medical chemistry, relates to a 2,4-dibasic miazines compound and specifically relates to a compound shown as formula (I) or a pharmaceutically acceptable salt thereof, a drug compound thereof and an application thereof in treating EGFR or/and ALK mediated diseases.

COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISEASES

The present invention refers to relates to compound for treating inflammatory diseases, said formula I compounds represented, such as, a pharmaceutically acceptable salts, or their, or a hydrate thereof is characterized in that the, polymerized. According to the present invention, interacting with-path 5-LOX a compound or interference, in particular 5- oh height[...]width it recovers sourly, in sacrifice, which display inhibitory effects can be provides compounds having. (by machine translation)

SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS

Provided are pyridopyrazine compounds of formula (1), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, R4 and m are as defined in the specification.

VEGFR TYROSINE KINASE INHIBITORS

Novel compounds, their prodrugs, and the pharmaceutically acceptable salts as pharmaceutical compositions containing such compounds useful in treating certain diseases modulated by the inhibition of vascular endothelial growth factors (VEGFs) receptor tyrosine kinases are provided. In particular, compounds and compositions and the methods for the prophylaxis, management and treatment of cancers through the inhibition of VEGF receptor tyrosine kinases are provided.

2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to novel pyrimide derivatives of formula (I): that are useful as kinase inhibitors. More particularly, the present invention relates to novel pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders.